Pregnancy Risks With First Trimester GLP-1 Continuation - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

  • By

  • Andrea Surnit

  • June 17, 2026

  • 3 min

Share

Clinical Scorecard: Pregnancy Risks With First Trimester GLP-1 Continuation

At a Glance

CategoryDetail
ConditionContinuation of GLP-1 receptor agonists during the first trimester of pregnancy
Key MechanismsGLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes.
Target PopulationPregnant women aged 16 to 55 years who received GLP-1 receptor agonist prescriptions prior to last menstrual period.
Care SettingObservational study using commercial insurance claims data.

Key Highlights

  • No clear increase in nonlive birth, abnormal fetal growth, or major congenital malformations with GLP-1 continuation.
  • 30% risk of nonlive birth in continuers vs. 27% in noncontinuers; adjusted risk ratio of 1.09.
  • Major congenital malformations found in about 8% of infants exposed to GLP-1 vs. 7% in noncontinuation group.
  • Elective termination more frequent among patients who continued treatment.
  • Similar rates of spontaneous abortion between both groups.

Guideline-Based Recommendations

Diagnosis

  • Monitor pregnancy outcomes in patients continuing GLP-1 receptor agonists.

Management

  • Consider individual patient circumstances regarding GLP-1 continuation during pregnancy.

Monitoring & Follow-up

  • Evaluate neonatal outcomes and potential risks associated with GLP-1 receptor agonist exposure.

Risks

  • Potential residual confounding related to glycemic control not fully measurable in claims data.

Patient & Prescribing Data

Pregnant women aged 16 to 55 years with prior GLP-1 prescriptions.

Most patients classified as continuers received only one additional prescription after conception.

Clinical Best Practices

  • Assess pregnancy intention and concerns about drug exposure in patients considering GLP-1 continuation.
  • Be aware of limitations in observational study designs when interpreting results.

Related Resources & Content

Original Source(s)

Pregnancy Risks With First Trimester GLP-1 Continuation

  • by Andrea Surnit

  • June 17, 2026

Related Content

Fertility Issues May Be Linked to Autism

In a nationwide US cohort, parental subfecundity was associated with higher odds of autism spectrum disorder and modest increases in behavioral symptoms, while in vitro fertilization showed no statistically significant associations with neurodevelopmental outcomes.

CHEST Issues OSA Guidance for Pregnancy

Guideline recommends screening, diagnosis, positive airway pressure therapy, and postpartum reassessment while highlighting the very low certainty of available evidence.

Could Pregnancy Complications Predict CVD Risk?

Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.